EGAGenomicsOtherhttps://ega-archive.org/studies/EGAS00001002566EGAEGA study EGAS00001002566GEPsCNAPsrestrictedEGAGiant Follicular Lymphoma, Disease, Small Lymphoid, Large Follicular Center-Cell, Follicular Large Cell, Nodular Histiocytic Lymphomas, follicular, Large-Cell Lymphomas, Immunotherapies., Follicular Mixed-Cell, Gene, Small and Large Cleaved-Cell, Client, Small Follicular Center-Cell Lymphoma, Brill-Symmers, Small Cleaved-Cell, Relative, Small and Large Cleaved Cell, Mixed Lymphocytic Histiocytic, Nodular Large Follicular Center Cell Lymphoma, Large Lymphoid Lymphoma, Follicular Large-Cell Lymphomas, Giant Follicular Lymphomas, Small Cleaved Cell Lymphoma, Relative Risks, Nodular Lymphomas, Mixed Cell, Nodular Histiocytic Lymphoma, Brill Symmers Disease, Mixed-Cell Lymphoma, Large Cell, Lymphomas, Nodular Lymphoma, Follicular, Giant, Large-Cell Lymphoma, Relative Risk, Mixed Small and Large Cell, Lymphocytic, Histiocytic Lymphoma, Follicular Lymphomas, Gene Expressions, Risk, Histiocytic, Risks, Mixed-Cell Lymphomas, Nodular Large Follicular Center-Cell Lymphoma, Small Follicular Center Cell, Follicular Mixed-Cell Lymphoma, Mixed Cell Lymphoma, Expressions, Small Cleaved Cell, Follicular Large-Cell Lymphoma, Small Follicular Center-Cell, Grade 1, Grade 2, Follicular Mixed-Cell Lymphomas, Grade 3, Large-Cell, Brill-Symmers Disease, Large Cell Lymphoma, lymphoma, Mixed Small and Large Lymphoid, Lymphocytic Lymphoma, Nodular Histiocytic, Large Follicular Center Cell, Histiocytic Lymphomas, Patient, Poorly-Differentiated, Small Follicular Center Cell Lymphoma, Nodular, Clients, Lymphoma, Follicular Large-Cell, Mixed Lymphocytic-Histiocytic, Giant Follicular, Follicular Lymphoma, Follicular Large Cell Lymphoma, Expression, Poorly Differentiated, Large Lymphoid, Small Cleaved-Cell Lymphoma, Mixed-Cell, Follicular Mixed Cell Lymphomafic, src-4, Materials, determination, Nodular Histiocytic Lymphomas, lymphomas non-Hodgkin's B-cell, Small Follicular Center-Cell Lymphoma, Brill-Symmers, Long Term, Small Cleaved-Cell, B Cell, Relative, Follicular Large-Cell Lymphomas, SRC 29A, btk29A, AT, Mixed-Cell Lymphoma, Fs(3)Hor, Lymphomas, Effect, Follicular, Mixed Small and Large Cell, treatment, Histiocytic Lymphoma, Dsrc28C, DmelCG2684, Prognoses, Biopsies, diffuse large B-cell lymphoma, long, Nodular Large Follicular Center-Cell Lymphoma, Small Follicular Center Cell, Follicular Mixed-Cell Lymphoma, btk, NTef2, c-src/fps, Large Cell Lymphoma, Dsrc29A, Large Follicular Center Cell, disease management, Mixed Lymphocytic-Histiocytic, Giant Follicular, Therapies, Diffuse Large B-Cell Lymphoma, "B-cell neoplasm (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:413616009], associated, ATK, B-cell non-Hodgkin's lymphoma, Long-Term Effects, Src29A, Therapy, Giant Follicular Lymphoma, B-Cell Lymphoma, Small Lymphoid, non-Hodgkin's B-cell lymphoma, Follicular Large Cell, Longterm Effect, B-cell non-Hodgkin lymphoma, results, CG18355, Fs(3)Sz11, Giant Follicular Lymphomas, Relative Risks, Nodular Lymphomas, Genetic Materials, IMD1, median, Nodular Histiocytic Lymphoma, Diffuse Large Cell, Nodular Lymphoma, Tec29A, Genetic Material, Large-Cell Lymphoma, Factors, death rate, Src2, Risk, Prognostic, follow up, PSCTK1, B-cell lymphocytic neoplasm, Treatments, CT2415, early, Diffuse Large-Cell, Follicular Mixed-Cell Lymphomas, Phenotypes, Brill-Symmers Disease, src4, lymphoma, Nodular Histiocytic, src28C, Patient, Material, Horka, Lymphoma, Follicular Large-Cell, CG2684, Fs(3)Horka, Follicular Large Cell Lymphoma, Cistron, Poorly Differentiated, src2, Follicular Mixed Cell Lymphoma, Diffuse Histiocytic, Prognostic Factor, DmelCG8049, Large Follicular Center-Cell, Effects, B-cell NHL, B-Cell, Dm SRC2, Gene, Prognostic Factors, C-src2, C-src4, Diffuse Large B Cell Lymphoma, Nodular Large Follicular Center Cell Lymphoma, Client., Large Lymphoid Lymphoma, Small Cleaved Cell Lymphoma, DTec29, DmF2, lod, Lymphocytic, DLBCL, Follicular Lymphomas, B-cell, Genetic, tec29, Longterm, Mixed-Cell Lymphomas, Long-Term, Mixed Cell Lymphoma, Follicular Large-Cell Lymphoma, Small Follicular Center-Cell, Diffuse, Large-Cell, Diffuse Large Cell Lymphoma, Mixed Small and Large Lymphoid, Histiocytic Lymphomas, Poorly-Differentiated, time of survival, Nodular, Clients, Follicular Lymphoma, Diffuse Large-Cell Lymphomas, Long-Term Effect, Tec29, dsrc29A, Disease, follicular, Large-Cell Lymphomas, xid, Follicular Mixed-Cell, DSrc28, Small and Large Cleaved-Cell, Factor, Cistrons, Client, Small and Large Cleaved Cell, Mixed Lymphocytic Histiocytic, survival, Large B-Cell, chemical analysis, Long Term Effects, S13, Mixed Cell, AGMX1, Brill Symmers Disease, CG8049, Large Cell, AI528679, Giant, Diffuse Large-Cell Lymphoma, BPK, CT41718, Relative Risk, distinct, Histiocytic, XLA, btk29a, Risks, non-Hodgkin's lymphoma B-cell, Lds, Small Cleaved Cell, B Cell Lymphoma, Longterm Effects, Grade 1, Grade 2, Grade 3, Diffuse Histiocytic Lymphomas, Lymphocytic Lymphoma, Therapeutic, Small Follicular Center Cell Lymphoma, Indexes, B-Cell Lymphomas, Diffuse Histiocytic Lymphoma, B-cell non Hodgkin's lymphoma, Treatment, Tec, assay, Large Lymphoid, Small Cleaved-Cell Lymphoma, Mixed-Cell, B-cell lymphomafalseCombined clinical and gene expression score identifies high-risk individuals among follicular lymphoma patients on immunotherapyFollicular lymphoma (FL) is usually an indolent malignant B-cell lymphoma, but at least 30% of the patients experience transformation to Diffuse Large B-cell Lymphoma (DLBCL) with inferior survival. Early identification of patients with poor prognosis is essential for tailoring treatment. Here, we describe a network-based integrative analysis of 168 FL-biopsies from 127 patients with long clinical follow-up and transformation status. A distinct shift in expression towards a DLBCL expression phenotype is observed in BTK associated genes in cases with transformation. This shift is present years prior to transformation. An integrated score combining the BTK score and a clinical index is proposed, termed the BTK-FLIPI score. It identifies patients (16%) with very poor prognosis, with median time to progression 21.7 months (95% CI: 14.3-42.6) versus 70.9 months (95% CI: 41.5-95.0) for the remainder. The results suggest BTK as a potential target for treatment of high-risk FL-patients.2023-07-11 08:13:01EGAS000010025669606EGAD00010002544EGAD00010002543EGAC00001000428